GRWD5769-ST-01
02 May 2023
Trial Summary
This study aims to assess a new cancer drug, GRWD5769, in patients with advanced cancer.
Acronym:
GRWD5769-ST-01
ACTRN/NCT /ethics:
ACTRN12623000108617
Scientific title:
A modular, multi-part, multi-arm, open-label, Phase I/II Study to evaluate the safety and tolerability of GRWD5769 in patients with solid malignancies – Module 1.
Sponsor / Cooperative group:
Grey Wolf Therapeutics Pty Ltd
Trial & Patient Characteristics
| Cancer Type | All |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | - |
| Anticipated Start Date | 2023-03-20 |
| Anticipated End Date | N/A |
Participating Hospitals
| Hospital | Southern Oncology Clinical Research Unit |
|---|---|
| Clinical Trial Coordinator | Meggan O'Riley |
| Meggan.Oriley@socru.org.au | |
| Phone | 0491 679 039 |
| Principal Investigator | Ganessan Kichenadasse |
| Recruitment Status | Recruiting |